Faculty

Lunchtime Symposium

Prof Seok-Soo Byun.png

Seok-Soo Byun

Korea

Professor

Dept of Urology, Seoul National University Bundang Hospital

 

Dr. Seok-Soo Byun graduated from Seoul National University College of Medicine in 1992. He finished a urological residency at Seoul National University Hospital. He has been working for the department of urology, Seoul National University Bundang Hospital (one of the branch hospitals of Seoul National University Healthcare Group) since its opening in 2003.

 

He is a uro-oncologist who cares for patients with prostate or kidney cancer. He has performed more than 3,000 robotic-assisted urologic cancer surgeries. His clinical interest also lies in medical care for patients with advanced prostate cancer and he is now actively involved in several international clinical trials using new investigative drugs for advanced prostate cancer. His main translation research activity is focused on identifying men with prostate cancer risk using germline genetic variants and making commercialized kits based on research findings. He has published over 400 peer-reviewed articles, 3 books and 10 domestic patents. He was awarded the best research paper from Korea Science and Technology Annual Meeting and best clinical paper from Korean Urological Oncologic Society in 2017. He is now serving as the vice president of the Korean Urological Research Society.

Prof.Miyake.JPG

Miyake Hideaki

Japan

Prof. Miyake Hideaki is a graduate of Kobe University School of Medicine (1993) who finished his PhD in the Department of Urology in 1998. He is currently Professor of Urology, Hamamatsu University School of Medicine. He is also an associate member of Vancouver Prostate Centre, University of British Columbia. Prof. Miyake is a Director of the Japanese Urological Association, and Editor-in-Chief of International Journal of urology, Official Journal of Japanese Urological Association and Urological Association of Asia. He has published more than 500 papers and his current research focuses on a wide range of topics associated with urological oncology.

Abstract : Prognostic significance of time to castration resistance in mCSPC

CF Ng 2018.jpg

Anthony CF Ng

Hong Kong

Dr NG Chi Fai, Anthony, graduated in the Chinese university of Hong Kong. After his basic training, he decided to become an urologist and became a specialist in 2001. Attracted by the rapid development in endourology, he spent one year in Scotland, worked under Mr David Tolley, and gained extensive experience in endo-laparoscopic surgery and stone management.

 

After completion of his training, Dr Ng decided to join the Chinese University of Hong Kong in 2006 and is currently Professor of the Division of Urology, Department of Surgery, the Chinese University of Hong Kong. He has a wide range of interest, in particular in prostate diseases, urolithiasis, and promotion of men’s health. He was also honored with the Outstanding Young Urologist Ward in 2010 by the Asian Congress of Urology, the International Guest Scholar 2012 of the American College of Surgeons, the Achievement award from the World Chinese Urology Association in the American Urological Association 2014 and the Outstanding Contribution Award by the International Alliance of Urolithiasis 2017.He is also the founding Chairman of Asian Urological Surgery Training and Education Group (AUSTEG).

ABSTRACT: Thiulium Fiber laser – the new standard of intracorporeal lithotripsy?

MJR_Photo.jpg

Maria J. Ribal 

Spain

  • Degree in Medicine and Surgery in 1994 from the University of Barcelona.

 

  • PhD Degree in Medicine and Surgery in 2002 from the University of Barcelona.

 

  • Specialist in Urology in 1999 after residency at the Hospital Clínic in Barcelona.

 

  • Consultant at Uro-Oncology Unit in Fundació Puigvert of Barcelona from 2002 to 2005. 

 

  • Senior Consultant of the Urology Department of the Hospital Clínic de Barcelona from 2009 to January 2015.

 

  • Head of the multidisciplinar Uro-oncology Unit of the Hospital Clínic de Barcelona from 2011 to the present day.

 

  • Fellowship for a period of 6 months, at University College London Hospital (UCLH) in the Laparoscopic Surgery Service of the Institute of Urology, under the direction of Prof. Mundy (July to December 2006).

 

  • Associate Professor in the University of Barcelona since September 2005.

 

  • Accredited as a researcher by IDIBAPS.

 

  • Member of the Muscle invasive and metastatic bladder cancer Guidelines Group of the European Association of Urology since 2006. Vice-Chair since 2018

 

  • Chair of the Dissemination Committee of the EAU Guidelines of the European Association of Urology from 2016 to the present day

 

  • Member of the European Urological Scholarship Program Office (EUSP) of the European Association of Urology since March 2012 till March 2020

 

  • Member of the Guidelines Office Board of the European Association of Urology (EAU) since October 2015.

 

  • Vice-chair EAU Guidelines Office from January 2019 until the current day. Chair-elect Guidelines Office from April 2021. 

 

  • President of the Societat Catalana d'Urologia (SCU)  (since April 2018) until current day.

 

  • >120 publications, > 350 Conferences in Courses, Congresses and Seminars.

 

  • Participation as principal investigator and collaborator in >30 clinical trials.

 

  • Collaborating Researcher HORIZON 2020 (Proposal ID 777492-; Call Identifier: H2020-JTI-IMI2-2016-10-two-stage) Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope Proposal acronym: PIONEER. (Coordinator: James N'Dow)

 

  • Member of the Research Group "Grup de Recerca urooncologic GRUO. Recognized by the Generalitat de Catalunya (SRG 1289).

 

  • Crystal Matula Award 2009 from the European Association of Urology awarded to urologist under 40 years of age with greater projection at European level.

ABSTRACT: Radical cystectomy for high-risk non muscle invasive bladder cancer: Who and Why?

MS_Photo.png

Mary Samplaski

United States

Mary Samplaski, MD is a fellowship-trained, board certified (American Board of Urology) urologist, and the Director of Male Infertility, Andrology and Microsurgery at the University of Southern California.  She completed her Urology residency at the Cleveland Clinic Foundation and Male Infertility and Andrology fellowship at the University of Toronto. 

 

Dr. Samplaski is a world leader in male infertility. She serves on the Board of Directors of the American Society of Reproductive Medicine, and Andrology Society of America. She has a strong record demonstrating a commitment to educational excellence and regularly presents her research on both domestic and international platforms. Her research interests include trainee education, ethics in reproductive medicine, and improving access to infertility care. Dr. Samplaski seeks to optimize male fertility care to help couples achieve a natural conception or improve outcomes with assisted reproductive technologies. In her personal time, Dr. Samplaski enjoys yoga, trivia, amateur ornithology, travel and escape rooms. 

 

ABSTRACT: Current Management of Non-Obstructive Azoospermia

Rafael Sanchez Salas

France

Dr. Rafael Sanchez-Salas, MD

Attending Surgeon, Department of Urology

L’Institut Mutualiste Montsouris

Université Paris Descartes.

Paris, France.

 

Rafael Sanchez-Salas is a surgeon and clinician scientist with main interest in minimally invasive treatments in Urological Oncology. He is an established leader in the field of Focal Therapy for the treatment of Localized Prostate Cancer. Dr. Sanchez-Salas earned his Medical degree from the Universidad de los Andes in Mérida, Venezuela; He was Valedictorian of the Class of 1998.  He completed his basic Surgical and Urological training at Universidad Central de Venezuela in 2005.

 

He was awarded with Scholarships from Confederation Americana de Urologia and The European Association of Urology to pursue fellowship training in urological oncology  and minimally invasive urological surgery at  Memorial Sloan Kettering Cancer Center in the US, Clinica Santa Maria in Chile and L’Institut Mutualiste Montsouris in France, where after his training  he joined the  Faculty in 2008. Dr. Sanchez-Salas has coined a sound international career as a talented surgical proctor (laparoscopy and robotics) and cancer researcher.  His current research priorities include Focal Therapy for Prostate Cancer and its impact on prostatic microenviroment and outcomes.  He Chaired the SIU-International Consultation on Urological Disease on Image guided therapy for Prostate and Renal Carcinomas in 2015.

 

In addition to his clinical, academic and research commitments, he has been responsible for fellowship (Advanced laparoscopy and Robotics) organization at the Department of Urology of  L’Institut Mutualiste Montsouris over the last 8 years. Dr Sanchez-Salas serves on Board of the Société International d’Urologie and the Robotic Urology Section of the European Association of Urology. He is a member of the Editorial Board for “European Urology Focus”, “The Journal of Endourology Part B, Videourology” and “Actas Españolas de Urologia”. He is a Reviewer for major Urological and Oncological journals. He has authored over 170 indexed scientific papers and is an internationally sought after speaker.

Yuh-Shyan Tsai

Taiwan

Dr Yuh-Shyan Tsai is a urological professor in Department of urology at National Cheng Kung University Hospital, College of medicine, National Cheng Kung University, Tainan, Taiwan. He was graduated from Kaohsiung Medical College in South Taiwan, and obtained Ph D from National Cheng Kung University. He also received post-Doc training at university of Texas southwestern medical center at Dallas. Clinically, he received resident training at NCKUH. Currently, he is a attending urologist and professor in NCKU. He is good at urological oncology and Da Vinci Robotic surgery.

Abstract : Latest treatment landscape of mCSPC

David Baunoch

California

David Baunoch, PhD

Chief Scientific Officer and Co-Founder 

Pathnostics

Irvine, California

David Baunoch received his PhD in microbiology and molecular genetics from Wayne State University and completed an NIH Postdoctoral Fellowship in Breast Cancer Research at the Michigan Cancer Foundation. Dr. Baunoch has more than 25 years of laboratory experience in a number of areas and has produced over 25 peer-reviewed publications. Before founding Pathnostics, he held a variety of executive management positions with industry-leading companies, including Ventana Medical Systems and US LABS, and was founder and president of Combimatrix Molecular Diagnostics.

Abstract : Advancements in Diagnosis and Treatment of Complicated, Persistent or Recurrent Urinary Tract Infections